Regeneron’s Eylea Tops Fourth-Quarter Sales Estimates
This article is for subscribers only.
Regeneron Pharmaceuticals Inc. reported fourth-quarter revenue of the eye drug Eylea, the company’s top-selling product, that beat analysts’ estimates. The shares rose the most in almost two years.
Sales were about $400 million last quarter, Chief Executive Officer Len Schleifer said today at the annual JPMorgan Chase & Co. health-care conference in San Francisco. The demand beat the $377.5 million average of eight analysts’ estimates compiled by Bloomberg.